• Sign up to our Free Newsletter
  • Contact Us
  • Editorial Submission
Microbiome Times Magazine
  • Human Health
  • Finance
  • Drug Database
    • Login
    • About
  • Issue Archive
  • Advertise
  • Recruitment Marketing

Editor’s Choice

Editor's Choice

Kaleido Biosciences Announces Positive Interim Results of Controlled Study of KB109 in Patients with Mild-to-Moderate COVID-19

January 20, 2021 Microbiome Times

Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced positive interim results from the K031 non-IND controlled clinical study evaluating outpatients with mild to moderate COVID-19 disease. Patients in this non-IND clinical study were randomized within 48 […]

Editor's Choice

Poor gut health connected to severe COVID-19, new review shows

January 18, 2021 Microbiome Times

People infected with COVID-19 experience a wide range of symptoms and severities, the most commonly reported including high fevers and respiratory problems. However, autopsy and other studies have also revealed that the infection can affect […]

Editor's Choice

First Published Clinical Trial Using Live Biotherapeutic Candidate In COVID-19 Patients Suggests Role In Improving Outcomes

September 25, 2020 Microbiome Times

ExeGi Pharma LLC, a U.S.-based company focused on developing and commercializing products targeting the human microbiome, including live biotherapeutic products (LBPs), announced today the results of a 70-patient clinical trial evaluating a new biologic drug […]

Editor's Choice

Seres Therapeutics Announces Positive Topline Results from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. difficile Infection

August 10, 2020 Microbiome Times

Seres Therapeutics, Inc. (Nasdaq: MCRB) today reported positive topline results from the pivotal Phase 3 ECOSPOR III study evaluating its investigational oral microbiome therapeutic SER-109 for recurrent C. difficile infection (CDI). The study showed that […]

Editor's Choice

The integral role of the microbiome in a post-pandemic world

August 10, 2020 Isabelle de Cremoux

At the beginning of 2020, I said to the Seventure team, that this would be the ‘Year of the Microbiome’.I still believe this will be true even in a COVID-19 world when our lives have […]

Editor's Choice

How viruses and bacteria balance each other in the gut microbiome

July 22, 2020 Microbiome Times

The adage “all things in moderation” applies not to just to food and drink, but also to the legions of bacteria inside our guts helping us digest that food and drink. It turns out the […]

Editor's Choice

Modelling Biology Using Graph Language

May 12, 2020 Sven Sewitz and Radouane Oudhriri

Abstract: At Eagle Genomics, we use graph databases to model the biological domain. This enables the scientist to access the relevant information and insight they are looking for in a number of industries, including pharmaceuticals, healthcare […]

Editor's Choice

Compositional Data Analysis Approaches to Improve Microbiome Studies – From Collection to Conclusions

May 12, 2020 Jean M Macklaim

Abstract: As vast amounts of high-throughput data are generated from sequencing the microbiome, suitable analysis approaches are needed to effectively evaluate the data and reach robust conclusions to power studies incorporating microbiome research questions. Sequencing […]

Editor's Choice

New Statistical Method Identifies Cytokines that Distinguish Stool Microbiomes

May 12, 2020 Bill Shannon

Abstract: A wide class of formal statistical methods exist that can be developed and applied to microbiome data. In this talk we present a statistical regression model. Regressing an outcome or dependent variable onto a set […]

Editor's Choice

Rebiotix and Ferring announce world’s first with positive preliminary pivotal Phase 3 data for investigational microbiome-based therapy

May 6, 2020 Microbiome Times

Today, Rebiotix and Ferring Pharmaceuticals announced positive preliminary findings from their ongoing pivotal Phase 3 trial of the investigational microbiome-based treatment, RBX2660. These preliminary positive efficacy findings mark an important milestone, advancing RBX2660 in its […]

Editor's Choice

Microbiome after coronavirus: Investing in the power of microbes

April 30, 2020 Luis Gosálbez

The COVID-19 crisis is causing immense suffering and an appalling death toll. It has also dramatically impacted our personal and professional lives, and individuals, businesses and investors can’t wait to get back to normalcy. However, […]

Posts navigation

« 1 … 6 7 8 … 14 »

Sign Up to Free Newsletter

The Microbiome Drug Database

Editor’s Choice

  • MRM Health Raises €55 Million Series B to Advance Microbiome-Based Biotherapeutic Product Pipeline
    September 4, 2025
  • Targeting the ileo-colonic region: Innovative solutions for sensitive APIs
    August 21, 2025
  • EXPERT’Biome CDMO by Lallemand at Microbiome Times Forum
    June 23, 2025
  • DynaMAP – Precision Metagenomics beyond Sequencing
    May 27, 2025
  • The Selection of a Pre-Clinical Model is Driven by the Specific Research Question
    May 13, 2025
sign up

Sign up to the Microbiome Times newsletter